Its suppression by insulin via downregulation of HNF4α links hepatic metabolic status to systemic hormonal control, establishing SHBG as a key mediator at the intersection of metabolic dysfunction, hyperinsulinaemia, and cancer risk (61). The gene discussed is SHBG; the disease is cancer.